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Abstract
Sensitivity of human fibroblasts derived from Down’s syndrome (DS) individuals (S-240, T-158, T-74, T-164) and normal donors (S-
126, WA-1) to anticancer antibiotic—mitoxantrone (1,4-dihydroxy-5,8-bis((2-((2-hydroxy-ethyl)amino)ethyl)amino)-9,10-anthracenedione
dihydrochloride; MIT) and its relationship to the transport rate, cellular distribution and interaction with cell membrane were studied. The
survival assay showed that MIT was more toxic to trisomic fibroblast lines than to normal cells. Studies of transport kinetics indicated that
the amount of drug taken up and extruded by DS cells was diminished, compared to control cells. In contrast, the cellular level of MIT
associated with DNA was greater in trisomic than in normal cells. The fluorescence anisotropy measurements of TMA-DPH and 12-AS
demonstrated that the fluidity of the polar region of the outer lipid monolayer of DS cell membrane was decreased in comparison with
normal cells. MIT treatment decreased fluidity of the inner hydrophobic region of plasma membrane, but only slightly influenced the
fluidity of the outer surface of the cell membrane. Finally, we concluded that lowered membrane fluidity, diminished amount of MIT
extruded by cells and the enhanced level of the drug associated with DNA could be responsible for the enhanced sensitivity of DS
fibroblasts to the MIT treatment.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Down’s syndrome (DS), caused by a complete or partial
trisomy of chromosome 21 (21q22.1), is one of the most
prevalent chromosomal aneuploidy in human liveborns [1].
In addition to mental retardation, DS is associated with
plenty of serious pathological disorders [2]. Individuals with
DS have pronounced risk of developing diabetes [3], Alz-
heimer’s type dementia [4] and haematological neoplasms
[5–7]. DS is, in particular, frequently associated with child-
hood cancer [8,9]. Affected children have a 10- to 30-fold
enhanced risk of acute lymphocytic leukemia (ALL) and
acute myeloid leukemia (AML), especially during the first 4
years of life [7]. Within the broad category of acute non-
lymphoblastic leukemias (ANLL), transient megakaryocytic
leukemia occurs almost exclusively in DS individuals and
the other form, acute nonlymphocytic leukemia subtype M7
(ANLL-M7) accounts for 50% of DS leukemias and is
extremely rare in the unaffected population [10].
The etiological role of chromosome 21-linked genes in
leukemogenesis is still poorly understood. Well-documented
biochemical defect that has been associated with DS is an
overexpression of Cu–Zn superoxide dismutase (SOD-1)
(EC: 1.15.1.1.), an enzyme catalysing the dismutation of
superoxide anion radicals to H2O2 and O2 [11]. Recently,
several new genes from the DS critical region have been
reported to be expressed at higher levels in the brain and
heart; however, the precise consequences of this require
further explanation [12,13].
The enhanced prevalence of malignant haematological
disorders in patients with DS makes the elucidation of the
specific response of trisomic cells to anticancer drugs of
special interest. In our study, we selected mitoxantrone (1,4-
dihydroxy-5,8-bis((2-((2-hydroxy-ethyl)amino)ethyl)a-
mino)-9,10-anthracenedione dihydrochloride) (novantrone;
MIT)—an antineoplastic drug, structurally related to anthra-
cyclines. MIT is the first fully synthesised tetracyclic
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anthracenedione derivative with two symmetrical amino-
alkyl side chains, introduced into cancer therapy in the late
1970s [14]. Since then, it has been commonly used for the
treatment of many neoplastic diseases such as leukemias,
sarcomas and breast cancers [15]. Generally, it is postulated
that like the anthracyclines, MIT intercalates into DNA and
causes DNA–protein cross-links and protein-associated
single-stranded and double-stranded breaks in the DNA
[16,17]. Moreover, MIT stabilises the DNA–topoisomerase
II cleavable complex and inhibits DNA synthesis [18]. The
ability of MIT to undergo one-electron reduction and gen-
erate free radicals in a manner similar to that of anthracy-
clines is considerably decreased [19]. Like anthracyclines,
MIT sensitises cells to both hyperthermia and ionising
radiation [20] and it can stimulate apoptosis in a variety
of cells [21].
Considering diminished DNA-repair capacity [22–24],
the disturbance of the reactive oxygen species metabolism in
DS persons [25] and the fact that cytotoxic effect of MIT is
related to DNA strand breaks and participation in free-radical
generation [19], it may be expected that the response of
trisomic ( + 21) cells to MIT treatment may be different than
that of non-DS cells. Currently available data, for obvious
reasons concern, first of all, different kinds of malignant
cells, whereas the cancer chemotherapy remains still largely
nonspecific and the majority of the antineoplastic drugs are
toxic to normal cells as well [14,15,20,26,27]. In this con-
text, the elucidation of the response of non-malignant cells to
anticancer drugs is of special importance. For this reason, the
purpose of this study was to compare the cytotoxicity, the
uptake dynamics and the interaction of MIT with cell
membranes of human normal (S-126 and WA-1) and triso-
mic, with respect to chromosome 21 (S-240, T-158, T-74 and
T-164) fibroblast lines.
2. Materials and methods
2.1. Drug and chemicals
MIT (novantrone) (1,4-dihydroxy-5,8-bis((2-((2-hydro-
xy-ethyl)amino)ethyl)amino)-9,10-anthracenedione dihy-
drochloride) was purchased from Pharmaceutical Company
Jelfa (Jelenia Go´ra, Poland); 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) and dimethyl sulf-
oxide (DMSO) were obtained from Sigma Chemical Co. (St.
Louis, MO). Fluorescence probes: 1-(4-trimethyl-ammo-
niumphenyl)-6-phenyl-1,3,5-hexatriene) (TMA-DPH) was
from Molecular Probes (Eugene, OR, USA) and 12-(9-
anthroyloxy)-stearic acid (12-AS) was from Sigma. The
Eagle minimal essential medium was supplied by Sera and
Vaccines Factory (Lublin, Poland) and Triton X-100 was
obtained from POCh (Gliwice, Poland). The newborn calf
serum and lactoalbumin hydrolysate were from Gibco BRL
(Edinburgh, Scotland). Gentamycin was purchased from
Biochemie G.m.b.H. (Vienna, Austria).
2.2. Cell lines and cell culture conditions
Human fibroblasts (Table 1) derived from DS persons (S-
240, T-158, T-74 and T-164) and from non-trisomic volun-
teers (S-126 and WA-1) were purchased from tissue bank of
the Centre of Child Health (Warsaw, Poland). Cell lines
were regularly tested to ensure they were free of contami-
nation or infections and re-established from frozen stocks at
periods of 3–4 weeks. Fibroblasts were routinely grown as a
monolayer in tissue culture flasks (Nunck; Naperville, IL,
USA), in a humidified atmosphere of 5% CO2 at 37 jC in
Eagle minimal essential medium supplemented with 10%
newborn calf serum, 10% lactoalbumin hydrolysate and
gentamycin solution (50 mg/cm3). For the experiments,
exponentially growing fibroblasts between the 5th and
15th passage were used.
2.3. Cell survival assay
The antiproliferative efficacy of MITwas examined in 96-
well flat-bottom microtiter plates (Costar, D. Dutscher,
France) by using the standard MTT colorimetric procedure
[28]. This indirect method is based on the ability of the
mitochondrial dehydrogenases of metabolically viable cells
to reduce the tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) to blue formazan product
which can be measured spectrophotometrically. For this
purpose, after trypsinization and cell counting, fibroblast
suspension was diluted in culture medium to achieve a final
cell density of 104 cells/cm3. Subsequently, 0.2 cm3 of this
cell suspension was seeded into each well of 96-well micro-
titer plates. After an overnight incubation, 0.05 cm3 of MIT
solution (at concentrations ranging 0–150 Amol/dm3 for
normal cell lines and 0–100 Amol/dm3 for DS cell lines)
was added and cells were incubated for 2 h (37 jC, 5% CO2).
Wells containing no drug were used as control and wells
containing no cells as blanks. After desired time, the MIT
solutions (or PBS in the case of control samples) were
discarded and replaced by fresh culture medium and cells
were allowed to grow for 3 days (37 jC, 5%CO2). Then, 0.05
cm3 of MTT solution in PBS (6 10 3 mol/dm3) was added
to each well and incubation was continued for further 4 h.
Subsequently, culture mediumwas removed and the resulting
formazan crystals were solubilised in 0.1 cm3 of DMSO. The
extent of MTT reduction to formazan within cells was
calculated by the measurement of the absorbance at 570
Table 1
Characteristics of the fibroblast lines
Cell line Karyotype Origin Donor age
S-126 46, XY skin 26 years
WA-1 46, XX skin 16 years
S-240 47, XY, + 21 skin 21 years
T-158 47, XX, + 21 skin 18 years
T-74 47, XX, + 21 fetus –
T-164 47, XX, + 21 fetus –
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nm, using a microplate reader (Awareness Technology Inc.,
Palm City, FL, USA). The percentage of survived cells was
calculated by dividing the mean absorbance values of the
drug-treated samples by that of untreated ones (control). The
IC50 values, defined as the drug concentration that reduces
cell proliferation to 50% compared with the untreated cells,
were determined directly from semilogarithmic concentra-
tion–response curves. Each experiment was performed in 6-
fold and was carried out independently six times.
2.4. Cellular drug accumulation and distribution
The studies on the dynamics of the MIT transport
through the cell membrane and the cellular partition of this
compound were carried out according to the modified
method [29], previously described by Andreoni et al.
[30,31]. For this purpose, the equal number of cells (106)
in 3 cm3 of culture medium was seeded into series of 35-mm
Petri dishes. After an overnight incubation (37 jC, 5%
CO2), medium was removed and replaced by 3 cm
3 of the
MIT solution (3 10 6 mol/dm3) in culture medium. An
equal volume of PBS was added to control samples. The
MIT solution (3 10 6 mol/dm3), without cells, was used
as references for initial drug concentration. At a desired
length of time of the MIT treatment, medium was aspirated
from dishes, to remove the drug not associated with the cell
monolayer and centrifuged (1500 rpm, 5 min). To estimate
the amount of the drug in supernatants, absorbance of the
samples at 610 nm, using a Cary 1 UV–Visible spectropho-
tometer (Varian, Australia Pty Ltd., Mulgrave, Australia)
was measured. The intracellular partition of MIT taken up
by cells between nucleus (DNA-bound drug fraction) and
the rest of the cell volume (free drug fraction) was deter-
mined as follows. Cell monolayers were washed gently
three times with 2 cm3 of PBS. Subsequently, 3 cm3 of
culture medium supplemented with Triton X-100 solution
(0.05%) was added to each dish, to permeabilize cell
membranes. After 15 min, medium with Triton X-100 was
transferred to a cuvette and absorbance at 610 nm was
measured. The quantity of drug in extracellular medium and
associated with cells were calculated from standard curves,
prepared by measuring the absorbance of known MIT
concentrations. All experiments were repeated five times.
To determine the parameters of MIT transport through
cellular membrane, a model of transport kinetics, involving
three compartments: (M)—extracellular medium containing
the M amount of drug; (F)—cellular compartment contain-
ing the F amount of relatively free drug; and (B)—contain-
ing the B amount of MIT associated with DNA, was
proposed. The cellular amount of drug (C =B + F) was
calculated from the following equation [31]:
C ¼ Mtot Mt ð1Þ
where: Mtot symbolises the total content of drug to which
fibroblasts were initially submitted and Mt is the amount of
MIT in external medium at various times of incubation.
Data representing the cellular content of the drug were
fitted to a third-order polynomial [determination coefficients
(R2) for plots were always greater than 0.95]. The initial
velocity of MIT uptake (It = 0) was calculated as a value of a
first derivative of the curve representing time dependence of
MIT amount in external medium. Uptake rate constants of
MIT transport were calculated according to the assumption
that MIT influx follows a first order equation [32,33]:
It¼0 ¼ kinMtot ð2Þ
where: kin is the influx rate constant.
The amount of drug taken up by cells (U) was next
calculated from the rate equation:
U ¼ Mtotð1 ekintÞ ð3Þ
The kinetic parameters for drug extruded by fibroblasts
(kout and Et = 0) were calculated in a similar manner from
curves representing the time dependence of the subtraction
of the intracellular amount of drug (C) from the amount of
drug taken up by cells (U) within the same time of MIT
treatment.
2.5. Fluorescence anisotropy measurement
To estimate the cell membrane fluidity of normal and DS
fibroblasts submitted to MIT treatment, the steady-state
fluorescence anisotropy (r) of fluorescence probes TMA-
DPH and 12-AS was measured. For this purpose, the same
number of fibroblasts (3 105 cells/cm3) suspended in 1.8
cm3 of culture medium was disposed into the set of test
tubes. Then, 0.05 cm3 of MIT solutions of various concen-
trations (2–100 10 6 mol/dm3) was added. Samples
containing cell suspensions in medium without drug were
Fig. 1. IC50 parameters (drug concentration reducing cell growth to 50% as
compared with untreated cells) for normal (S-126 and WA-1) and trisomic
(S-240, T-158, T-74 and T-164) human fibroblasts treated with MIT. Data are
expressed as meansF S.D. for six independent experiments. * Significantly
different when compared to the mean value obtained for normal cell lines
( P< 0.001).
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used as controls. After incubation (2 h in humidified
atmosphere of 5% CO2, at 37 jC), samples were centrifuged
(1500 rpm, 5 min), the supernatant was aspirated and the
cell pellet was resuspended in 1.8 cm3 of PBS. To determine
cell membrane fluidity, fibroblast suspensions were incu-
bated either with TMA-DPH or 12-AS (final concentration
in samples—10 6 mol/dm3) at room temperature for 5 or 10
min, respectively. The measurements were carried out with a
Perkin Elmer spectrofluorometer model LS-5 B (Beacons-
field, Buckinghamshire, England). The excitation and the
emission wavelengths were kex = 358 nm and kem = 428 nm
for TMA-DPH and kex = 360 nm and kem = 471 nm for 12-
AS. Fluorescence anisotropy was calculated according to
the equation [34]:
r ¼ ðIvv  IvhGÞ=ðIvv þ 2IvhGÞ ð4Þ
where: Ivv and Ivh are the intensities of the light emitted,
respectively, parallel and perpendicular to the direction of
the vertically polarised excitation light and G (Eq. (5)) is the
correction factor for the optical system, given by the ratio of
the vertically to the horizontally polarised emission compo-
nents when the excitation light is polarised in the horizontal
direction:
ðG ¼ Ihv=IhhÞ ð5Þ
According to Shinitzky and Barenholz [34], the fluores-
cence anisotropy values are inversely proportional to cell
membrane fluidity. A high degree of fluorescence aniso-
tropy represents a high structural order or low cell mem-
brane fluidity. Studies on membrane fluidity performed with
two fluorescent probes TMA-DPH and 12-AS which locate
in different regions of the bilayer yield information about
the rigidity of the cell membrane near the lipid polar heads
(TMA-DPH) [35] and inside the hydrophobic lipid core (12-
AS) [36]. All the fluorescence measurements were corrected
Fig. 2. Time dependence of MIT taken up (E) and MIT removed ( ) by human normal (S-126 and WA-1) and trisomic (S-240, T-158, T-74 and T-164)
fibroblasts. (.)—amount of drug in external medium. (n)—amount of drug associated with cells. Data are expressed as meansF S.D. for five independent
experiments.
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for the contribution of light scattering by performing control
experiments on cells without fluorescent probes added and
were repeated six times.
2.6. Statistical analysis
All data were expressed as mean and standard deviation
of five or more separate experiments. One-way analysis of
variance (ANOVA) with post hoc multiple comparisons
procedure (Tukey test) were used to assess statistical differ-
ences in this study. A P-value of less than 0.01 was
considered statistically significant. All statistical analyses
were done using STATISTICA software (2000) (StatSoft,
Inc., Tulsa, OK, USA).
3. Results
3.1. Cellular sensitivity to MIT
The cell survival assay showed that the exposure of
human fibroblasts to MIT resulted in a successive decrease
of cell survival. Comparison of the IC50 values, determined
directly from dose–response curves (data not presented), for
normal (S-126, WA-1) and trisomic (S-240, T-158, T-74, T-
164) cell lines (Fig. 1), indicated that antiproliferative
efficacy of MIT was significantly higher for fibroblasts
derived from DS individuals (average: 41.50F 4.60 Amol/
dm3) than for normal (average: 94.13F 7.96 Amol/dm3) cell
lines (P < 0.01).
Fig. 3. Cellular distribution of MIT in normal (S-126 and WA-1) and trisomic (S-240, T-158, T-74 and T-164) human fibroblasts. M—amount of MIT in
external medium; F—amount of cellular free MIT; B—amount of MIT bound to DNA. Data are expressed as meansF S.D. for five independent experiments.
* Significantly different when compared to the mean value obtained for normal cell lines ( P< 0.001).
Table 2
Transport parameters of MIT in human normal (S-126 and WA-1) and trisomic (T-164, S-240, T-158 and T-74) fibroblasts













A S-126 2.65F 0.11 0.238F 0.010 7.17F 0.14 9.60F 0.81 8.64F 0.73 3.28F 0.11
B WA-1 2.57F 0.12 0.231F 0.011 7.08F 0.16 7.94F 0.86 7.14F 0.78 3.15F 0.10
DS cells
C S-240 2.15F 0.98 0.194F 0.009 6.53F 0.12 2.28F 0.16 2.05F 0.14 1.76F 0.12
D T-158 2.17F 0.96 0.195F 0.008 6.55F 0.13 2.61F 0.15 2.35F 0.13 1.87F 0.13
E T-74 2.19F 0.13 0.197F 0.011 6.58F 0.16 2.93F 0.20 2.63F 0.18 1.96F 0.14
F T-164 2.19F 0.12 0.197F 0.011 6.57F 0.16 2.74F 0.18 2.46F 0.16 1.89F 0.15
ANOVA I
F 21.71 21.71 21.82 241.15 241.15 178.52
df 5; 30 5; 30 5; 30 5; 30 5; 30 5; 30
P < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Tukey’s test AB CDEF AB CDEF AB CDEF A B CDEF A B CDEF AB CDEF
Kin—influx rate constant; It = 0—initial influx; Ut = 60—drug taken up by cells within 60 min; Kout—efflux rate constant; Et = 0—initial efflux; Et = 60—drug
removed by cells within 60 min. Data are expressed as meansF S.D. for six independent experiments.
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3.2. Transport kinetics and cellular distribution
The transport kinetics of MIT through cellular mem-
brane, estimated indirectly from the measurement of the
drug absorbance in external medium, indicated the sub-
stantial differences in cellular uptake of this compound by
normal and DS cells. The analysis of curves representing
the time dependence of the amount of drug taken up and
extruded by cells, during the same time (Fig. 2), and the
kinetic parameters, calculated from them (Table 2), showed
that the amount of drug taken up for 60 min of incubation
was greater for normal (average: 7.13F 0.15 nmol/106
cells) than for DS cells (average: 6.56F 0.15 nmol/106
cells). Comparison of the values representing the amount of
MIT removed by fibroblasts during 60 min of incubation
(average: 3.22F 0.12 nmol/106 cells—normal cells;
1.87F 0.15 nmol/106 cells—trisomic cells) suggests that
efflux of MIT from cells was markedly lowered in DS
fibroblast lines as compared to non-trisomic ones (Table 2).
Analysis of the cellular distribution of MIT (Fig. 3)
showed that the amount of MIT bound to DNA is greater
for DS fibroblast lines (average: 1.97F 0.11 nmol/106 cells)
than for normal cells (average: 0.98F 0.08 nmol/106 cells).
In contrast, no statistically significant differences in the
amount of cellular free MIT, between normal and trisomic
fibroblasts (average: 2.92F 0.17 nmol/106 cells—normal
cells; 2.73F 0.14 nmol/106 cells—trisomic cells) were
observed.
Fig. 4. Influence of MIT on fluorescence anisotropy of TMA-DPH in normal (S-126 and WA-1) and trisomic (S-240, T-158, T-74 and T-164) human
fibroblasts. Data are expressed as meansF S.D. for six independent experiments. * Significantly different when compared to value obtained for non-treated
cells ( P < 0.01).
Fig. 5. Effect of MIT on fluorescence anisotropy of 12-AS in normal (S-126 and WA-1) and trisomic (S-240, T-158, T-74 and T-164) human fibroblasts. Data
are expressed as meansF S.D. for six independent experiments. * Significantly different when compared to value obtained for non-treated cells ( P < 0.01).
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3.3. Cell membrane fluidity
The fluorescence anisotropy values of fluorescent dyes
TMA-DPH and 12-AS, calculated for untreated cells,
showed that the DS fibroblasts had (P < 0.01) lower
fluidity near the outer polar surface of cell membrane
(average: r= 0.296F 0.007) than control cells (average:
r = 0.268F 0.007) (P < 0.01) (Fig. 4). Contrary to this, the
fluidity of the hydrophobic lipid region of the cell membrane
was nearly the same for both cell types (average: r = 0.131F
0.005—normal cells; r = 0.135F 0.006—trisomic cells)
(Fig. 5).
The comparison of anisotropy fluorescence values of 12-
AS indicated that association of MIT molecules with plasma
membrane decreased their fluidity in the hydrophobic region
of normal as well as trisomic cells, especially for drug
concentrations above 5 Amol/dm3 (Fig. 5). For the highest
MIT concentration applied (100 Amol/dm3), the fluores-
cence anisotropy of 12-AS increased, in average, from
0.135 to 0.280 in DS fibroblasts and from 0.131 to 0.263
for normal cells. In contrast, MIT treatment only slightly
influenced the fluidity of the outer surface of the cell
membrane. The fluorescence anisotropy values of TMA-
DPH demonstrated statistically significant differences
(P < 0.01) only at the highest doses tested (Fig. 4).
4. Discussion
Biochemical disturbances of the reactive oxygen species
metabolism revealed in subjects with DS make trisomic
cells a convenient model system with the potentially altered
resistance both to internal as well as external sources of free
radicals [25,37]. Increased level of Cu–Zn superoxide
dismutase (SOD-1) (EC: 1.15.1.1.), an enzyme coded on
distal half of the long arm of 21 chromosome, is considered
as a cause of an excessive production of H2O2 and con-
sequently for a constant elevation of oxidative stress in
trisomic cells [11,25]. Under such conditions, the balance
between the production of free radicals and the ability of the
cell antioxidant defence system may be disturbed [38,39].
Reports comparing in vitro as well as in vivo sensitivity
of normal and DS cells of various origins to MIT treatment
have resulted in different conclusions depending on the
tested cells [40,42]. Our in vitro investigations of the
influence of MIT on the survival of human normal (S-126
and WA-1) and trisomic (S-240, T-158, T-74 and T-164)
fibroblast lines (Table 1) indicated that the sensitivity of DS
cells to MIT treatment was significantly elevated (P < 0.01),
in comparison to diploid cells (Fig. 1). Greater in vitro
sensitivity of cell lines derived from DS individuals was
confirmed by results obtained by several oncological pedia-
tric groups which reported that AML in children with DS
has a significantly better outcome than AML in non-DS
children [42,43]. Our results are as well in accord with data
obtained by Kaspers et al. [41], who found the 26.2-fold
growth inhibition of ANLL cells of DS patients submitted to
in vitro MIT treatment as compared to those, derived from
non-trisomic ANLL individuals. Moreover, trisomy of 21
chromosome has been reported as one of the largest risk
factor for the development of MIT-associated cardiotoxicity,
greatly decreasing a survival rate of DS patients [44].
The IC50 values obtained in our examinations for normal
as well as DS fibroblast lines (Fig. 1) were at least 10 to 200
times greater compared with the most currently available
data reported for various kinds of malignant cells [45,46].
The above findings might imply that non-malignant cells
were more resistant to MIT antiproliferative activity than
tumour cells. Our results agree with the recent finding
published by Andersson et al. [47], who obtained relatively
high IC50 values varying from 57 to 72 Amol/dm3 for
isolated rat cardiomyocytes. Similar results were reported
by Dorr et al. [46], who using the in vitro cytotoxicity
assays in human 8226 myeloma cells and neonatal rat heart
myocytes, obtained IC50 values for MIT in rat heart cells
approximately 500-fold higher than that calculated for
tumour cells.
Sensitivity of DS cells to various anticancer drugs, as
compared to normal ones, is also related to the kind of the
examined compound. In our previous studies, we examined
cytotoxic effect of daunorubicin [29] and aclacinomycin
(data submitted to publication)—anthracycline antibiotics
closely related to MIT and we found that DS cells were
considerably less sensitive to damage mediated by those two
drugs. Similar results were reported by Ro´zga and Duong
Thi Bach [48] who, on the basis of the kinetics of the 51Cr
release and by MTT and colony forming ability assays,
showed significantly decreased sensitivity of trisomic DS
fibroblast cell lines to carminomycin compared to diploid
non-DS cells. Nevertheless, the same trisomic cell lines
appeared to be more sensitive to g-radiation which presum-
ably indicated the enhanced number of unrepaired DNA
double-strand breaks, leading to reproductive death of these
cells.
Explanation for the mechanism of greater or lower
susceptibility of cells derived from DS individuals to
various chemical and physical agents compared to non-
trisomic cells is still open to question. It may be postulated
that DS cells are, in general, more sensitive to the anticancer
therapeutic agents whose molecular efficacy may be exerted
mostly by the direct or indirect interaction with DNA or
with the various DNA-bound proteins, leading to the block-
ing of the transcription or mediated DNA strand break. In
this case, the increased sensitivity of DS cells appears to be
caused by the diminished DNA-repair capacity [23,24].
The finding [49] that oxidation of MIT was enhanced by
SOD-1 might be a crucial point for the explanation of
increased susceptibility of DS cells to this compound. A
number of studies demonstrated that in individuals with DS,
the activity of SOD-1 and GPX were markedly elevated
while catalase and glutathione reductase activities were
normal in variety of cell types [38,50]. It might therefore
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be speculated that, although the cellular level of superoxide
radicals in DS tissues was decreased, the production of
H2O2 was enhanced.
There is common agreement that the antiproliferative
efficacy of MIT, likewise many other anticancer drugs,
depends on the concentration achieved in compartments
where its cellular targets are located. The final cellular
steady state of MIT is the result of the numerous individual
processes such as, uptake and efflux, distribution among
cellular organelles and binding to various intracellular sites.
The currently available data confirm the assumption that
uptake of MIT, similarly to anthracycline antibiotics, occurs
by passive diffusion [32,33]. The mechanism according to
which cells extrude this compound still remains unknown
[32]. Burns et al. [32], who investigated transport of radio-
labeled MIT by cultured mouse L1210 leukemia cells,
found that the efflux of this compound was not affected
by KCN or verapamil and was not energy requiring. In
contrast, the results published by Coloma et al. [33] showed
that MIT transport might also involve an energy-dependent
drug efflux pump similar to P-glycoprotein and multidrug
resistance-associated protein carrier.
In our investigations, we found that MIT was rapidly
taken up and distributed in the cellular compartments of all
cell lines studied; however, the kinetics of drug transport
through cell membranes were different in DS and non-DS
fibroblasts (Fig. 2). Comparison of the influx and efflux rate
constants as well as initial influx and initial efflux values
(Table 2) demonstrated that the amount of drug taken up and
removed, within the same time, by DS fibroblasts, was
substantially lower than by normal cells. These data are
confirmed by results reported by Koter et al. [51]. They
indicated that the transport of a hydrophobic spin label
probe-TEMPO across the erythrocyte membrane, studied
by ESR method, was significantly slower in DS cells than in
non-trisomic ones.
Further analysis of our data showed that the level of
intracellular MIT content, being a function of the amount of
drug transported inside the cell (influx) and the amount of
drug expelled out of cell (efflux), was greater in trisomic
than in normal cells (Fig. 3). Enhanced accumulation of
MIT by DS cells probably resulted from substantially
decreased drug efflux (Table 2). Comparison of cellular
distribution of MIT showed that the fraction of MIT mole-
cules considered as DNA-bound MIT was greater in triso-
mic cells as well. At the same time, no differences between
normal and DS cells in the amount of the cellular free drug,
associated with other than nucleus cellular structures, were
found.
Different patterns of intracellular MIT distribution in
trisomic and normal cells, provided by our study, corrobo-
rated results reported by Davies and Doroshow [52], who
found predominant nuclear localization of this drug in cells
more sensitive to MIT. Moreover, Feofanov et al. [53], using
confocal spectral imaging technique, for quantitative anal-
ysis of the uptake, subcellular localization, and character-
istics of localised binding and retention of MIT within
human K562 erythroleukemia cells, found growing accu-
mulation of MIT bound to nucleic acids within the nucleus
in the cells treated with a high concentration of this drug.
Little is known about the interaction of MIT with differ-
ent components of cell membranes and particularly about its
influence on cellular drug uptake. Burns et al. [32], who
studied the effect of membrane structural alteration on the
cellular association of the MIT in L1210 cells, modified by
incubating them with the highly unsaturated docosahexae-
noic acid (22:6) or with the monounsaturated oleic acid
(18:1), have found that the rate of uptake by 22:6-enriched
cells during the first minutes was 62% greater than by those
enriched with 18:1 acid. The difference in cell-associated
drug was apparently not due simply to a change in MIT
solubility as measured by partitioning of the drug in lip-
ophilic–hydrophilic systems containing lipids from the
fatty-acid altered cells. They concluded that the type of
fatty acids contained in L1210 cell membranes might affect
the cell association of MIT. This effect could be on trans-
membrane flux or be due to differences in binding of the
drug to intracellular structures [54].
We have also studied the relationship between sensitivity
of normal and trisomic fibroblast lines to MIT injury and
fluidity of the cell membrane, a parameter commonly
considered as an important aspect of cellular physiology
and an essential factor for cell integrity and survival and as
well responses for numerous cancer cells properties, such as
invasiveness and growth features [55].
For this purpose, we selected spectrofluorometric method
based on the measurement of the fluorescence anisotropy of
the lipid probes TMA-DPH and 12-AS. A major advantage
of choosing TMA-DPH and 12-AS is that these fluorescent
dyes are confined primarily to the plasma membrane [34]
and yield information about the rigidity of the cell mem-
brane near the lipid polar heads [35] or inside the hydro-
phobic lipid core, respectively [36].
Anisotropy values obtained for the fluorescent probe-
TMA-DPH, presented in Fig. 4, show that untreated DS
fibroblasts have substantially lower fluidity at the outer
surface of the lipid monolayer of the cell membrane (higher
anisotropy) (0.296F 0.007) than control cells (0.268F
0.007) (P < 0.01). In contrast, no statistically significant
difference in rigidity at the inner, hydrophobic lipid region
of the cell membrane, between normal and DS fibroblasts
(0.131F 0.005—normal cells; 0.135F 0.006—trisomic
cells) (Fig. 5), was observed. A high fluorescence aniso-
tropy of TMA-DPH, related to low cell membrane fluidity,
suggests an increase of structural order at the lipid–water
interface region of DS cell membrane.
The relationship between the decreased cell membrane
fluidity of DS individuals and cell membrane composition
has still been under discussion. Data obtained by Kantar et
al. [56] suggested that the critical factors influencing cell
membrane fluidity, that is, phospholipid and cholesterol
capacity and the cholesterol to phospholipid molar ratio,
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are almost equal in cell membranes from DS persons and
normal non-trisomic donors. The analysis of the content of
polyunsaturated fatty acids in cell membranes [38] indicated
significant alterations of the relative proportion of various
groups of these compounds. The linoleic acid content as
well as elongated products of arachidonic acid (adrenic acid,
docosatetraenoic acid and docosapentaenoic acid) were
markedly diminished in trisomic individuals. On the other
hand, the amount of long-chain polyunsaturated fatty acids
(dihomo-g-linolenic acid and arachidonic acid) and doco-
sahexenoic acid were enhanced in DS cells, compared with
the control group. Moreover, data obtained by Keˆdziora et
al. [57,58] as well as Chapman et al. [59] indicated the
existence of structural modifications of trisomic cells sug-
gesting the loss of membrane surface. They concluded that
protein conformational changes, revealed by scanning elec-
tron microscopy examinations, were rather responsible for
membrane structural alterations of DS cells, than the cell
membrane lipid composition or the degree of the acyl-chain
unsaturation themselves.
We also examined the effect of MIT treatment on cell
membrane fluidity. Association of MIT molecules with
plasma membrane markedly decreased their fluidity in the
hydrophobic region of normal as well as trisomic cells in the
drug concentration-manner (Figs. 4 and 5). Contrary to this,
MIT treatment influences the fluidity of the outer surface of
the cell membrane only at higher drug doses applied.
Moreover, we indicated that the extent of the rigidization
of outer as well as inner domains of cell membrane was
greater for all trisomic fibroblast lines compared to normal
ones. These facts suggest that MIT molecules were prefer-
entially accumulated in the inner hydrophobic core of cell
membrane and that the association of MIT with trisomic cell
membranes was altered, as compared to normal fibroblast
lines.
In summary, the data presented in this paper suggest that
the cellular mechanism of antiproliferative action of MIT in
DS cells appears to be different than that of anthracyclines
such as daunorubicin and aclarubicin. Lower membrane
fluidity observed in trisomic fibroblasts might diminish
influx and efflux rates and finally increase drug accumu-
lation level. Alterations of cell membrane fluidity and
differences in drug transport suggest that the plasma mem-
brane is an important site of MIT accumulation and action.
The greater cellular accumulation of MIT in trisomic cells,
especially the drug fraction interacting with DNA, could be
responsible for the decreased survival of cells derived from
DS patients.
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